Acta Pharmacologica Sinica (2018) 39: 845–857
© 2018 CPS and SIMM All rights reserved 1671-4083/17
www.nature.com/aps

Review Article

Organ preservation: from the past to the future

Lei JING[1, 2], Leeann YAO[2], Michael ZHAO[2], Li-ping PENG[1, *], Mingyao LIU[2, *]

[1]Department of Respiratory Medicine, The First Bethune Hospital of Jilin University, Changchun 130021, China; [2]Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network; Department of Surgery and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada

Abstract

Organ transplantation is the most effective therapy for patients with end-stage disease. Preservation solutions and techniques are crucial for donor organ quality, which is directly related to morbidity and survival after transplantation. Currently, static cold storage (SCS) is the standard method for organ preservation. However, preservation time with SCS is limited as prolonged cold storage increases the risk of early graft dysfunction that contributes to chronic complications. Furthermore, the growing demand for the use of marginal donor organs requires methods for organ assessment and repair. Machine perfusion has resurfaced and dominates current research on organ preservation. It is credited to its dynamic nature and physiological-like environment. The development of more sophisticated machine perfusion techniques and better perfusates may lead to organ repair/reconditioning. This review describes the history of organ preservation, summarizes the progresses that has been made to date, and discusses future directions for organ preservation.

Keywords: organ transplantation; organ preservation; static cold storage; machine perfusion; organ assessment; organ repair; ischemia-reperfusion injury

Acta Pharmacologica Sinica (2018) 39: 845–857; doi: 10.1038/aps.2017.182; published online 22 Mar 2018

Introduction

Organ transplantation is the only effective therapy for patients with end-stage disease in many cases. A number of factors have contributed to the success of organ transplantation, including organ preservation, surgery, immunosuppressive medication, and post-transplantation care. A supply of high-quality donor organs is crucial to transplantation procedures; organ preservation has been described as "the supply line for organ transplantation"[1]. It allows time for preparation of the recipient, organization of staff and facilities, allocation and transportation of the organ, and laboratory tests[2,3].

Static cold storage (SCS) offers a simple and effective way to preserve and transport organs and is the most commonly used method[4]. However, a number of limitations are associated with SCS, including tissue damage induced by prolonged hypothermic preservation, difficulty in assessing donor organ function and viability, inevitability of ischemia-reperfusion injury (IRI), and limited opportunity for organ repair. Recently, the growing use of marginal organs from extended criteria donors has led to an emergence of *ex vivo* lung perfusion (EVLP) to assess donor lung function[5,6]. In addition to being an excellent graft assessment tool, EVLP has also shown potential for enabling graft repair, reconditioning, and immunomodulation[7], which inspired similar research and clinical applications in other organ systems[8–10]. The desire to extend preservation times has motivated research on optimal preservation solutions, temperatures, techniques, and therapeutic additives for organ repair and reconditioning[11–14]. By reviewing the history of organ perfusion and preservation, we noted that before the introduction of SCS in 1960s[15], machine perfusion with plasma or blood-based solutions was the clinical method for preserving isolated organs[16,17]. Reevaluating the advantages and limitations of early organ perfusion/preservation may help with the development of new techniques/solutions that enable prolonged safe preservation and the repair of extended criteria donor organs to address the organ shortage issue. Theories, preservation techniques, preservation solutions, and clinical practices are discussed.

*To whom correspondence should be addressed.
E-mail mingyao.liu@utoronto.ca (Mingyao LIU);
plp640317@163.com (Li-ping PENG)
Received 2017-10-21 Accepted 2017-12-31

Past: a story of organ perfusion and preservation

Primitive concepts underwent a number of modifications over decades of scientific exploration to arrive at current practices in organ perfusion and preservation. It is essential to under-

stand this history to be able to evaluate the future direction of this field of research.

Organ perfusion as a primitive preservation technique

Organ preservation developed from the primitive concept of extracorporeal circulation, which first emerged in 1812 in the monography of Cesar Julien Jean Le Gallois. He speculated that "if the place of the heart could be supplied by injection—and if, for the regular continuance of this injection, there could be furnished a quantity of arterial blood, whether natural or artificially formed, supposing such a formation possible—then life might be indefinitely maintained in any portion"[18]. In 1849, German scientist Carl Eduard Loebell described in his Dissertation Inaugurals the first perfusion experiments on isolated pig kidneys. He observed that the bright red arterial blood perfused through porcine kidneys became dark and viscous upon its course through the renal veins[19]. In 1885, Max von Frey and Max Gruber constructed the first closed artificial circulation system, which shares many similarities to today's organ perfusion systems[20]. In 1895, Jacobj created a double circulation apparatus, which used an isolated lung as an oxygenator and permitted organ perfusion for several hours[19]. These early studies led to the development of extracorporeal membrane oxygenation (ECMO) and the subsequent development of perfusion systems for organ preservation[19–24].

From blood to chemically defined perfusion solution

Historically, blood was used as perfusate in early apparatuses. Primitive perfusion apparatuses required a large supply of blood to operate, whereby the volume of an animal's own blood was insufficient. People tried to substitute an animal's own blood with blood from a different animal species. The use of cross-species blood was toxic to the graft and led to its rapid decline[25]. Scientists then diluted the animal's own blood with normal saline or Ringer's solution. These methods led to the development of severe edema in organs, especially in the lung[25]. These early studies led to the realization of xenoimmunity and the development of transfusion solutions.

In 1937[26], Alexis Carrel perfused isolated cat thyroids in the Lindbergh apparatus with Tyrode's solution comprised of glucose, ions, and 40%–50% homologous serum. He found that the organs were viable for 3–21 days. However, cultivation over 6 days showed a tendency towards hyperplasia. In 1968[27], Hou *et al* cultured normal human placentas in a chemically defined culture medium. Placentas were kept viable for at least 14 days, but the stroma underwent great modification within 3 days. These studies demonstrated that organs or tissues were capable of surviving outside of the body for several days under normothermic conditions in culture medium. However, maintaining the normal histological morphology of cultured organs raised challenges, which slowed down organ culture research for several decades.

Temperature: from normothermic to hypothermic

Originally, organs were perfused at room temperature. In 1876, Bunge and Schmiedeberg added a water bath to the circuit to maintain perfusion blood at physiological temperatures[19]. Later, scientists began to speculate that the use of lower temperatures might attenuate organ damage during perfusion by abating cellular metabolism. In the 1960s, a number of experiments were performed with cooled diluted serum or heparinized blood, and kidney perfusion was extended from hours to days[28,29]. However, the use of cold blood also caused many problems, such as vascular spasm in kidney grafts[30].

From dynamic to static modality

In the 1960s, kidneys were successfully preserved for 3–5 days by continuous perfusion with cooled, oxygenated blood or plasma[28,29]. However, this method required complex and costly equipment, which limited its availability and made the transportation of organs extremely difficult. In 1969, Collins GM was able to successfully preserve canine kidneys for 12 h by immersing them in iced saline solution, and he later further prolonged cold storage time to 30 h with Collins solution[15,31]. This simple method for organ preservation was more cost-efficient and convenient for organ transportation than its predecessors. The birth of SCS replaced dynamic perfusion methods and became the standard method of organ preservation.

Present: current practice and research on organ preservation

Preservation techniques (temperature, apparatus, perfusion setting, *etc*) and perfusion solutions are the major fields of research in organ preservation.

Static cold storage and preservation solutions

Since the 1960s, SCS has gradually become the gold standard method for organ preservation. SCS involves flushing the procured organ with preservation solution at 0–4 °C, then immersing it into preservation solution at the same temperature until transplantation. The hypothermic environment is responsible for decreasing cellular metabolism, and the preservation solution reduces cellular metabolism and provides cytoprotection.

Collins solution was the first preservation solution to enter the commercial market in 1969[15]. It was used to preserve the kidney, heart, liver, and lung grafts. In 1980, Collins solution was modified via impermeant composition and improved chemical stability. The new solution was named a Euro-Collins solution, and it provided better protection during prolonged cold ischemia and was widely used[2,32]. The University of Wisconsin (UW) solution was introduced in the mid-1980s[33] and continues to be used today for abdominal organ preservation[34]. These solutions are so-called intracellular fluid (ICF)-type solutions characterized by low Na^+ and high K^+ concentrations. ICF-type solutions were intended to prevent cellular edema by maintaining intracellular ion concentrations upon cold-induced dysfunction of Na^+/K^+ pumps[35].

Adding amino acids to the preservation solution and using a histidine buffer system led to the development of histidine-tryptophan-ketoglutarate (HTK) solution, which is characterized by low K^+ and low Na^+ concentrations. It was originally

Table 1. Composition of popular cold preservation solutions.

Solutions	EC	UW	HTK (Custodiol)	Custodiol-N	Celsior	LPDG (Perfadex)	Ep4 (EP-TU)	ET-Kyoto	IGL-1
K^+	115	125	10	10	15	6	26	44	30
Na^+	10	25	15	16	100	138	141	100	125
Cl^-	15	20	32	30	71	142	103	–	–
Ca^{2+}	–	–	0.015	0.02	0.25	–	–	–	0.03
Mg^{2+}	–	5	4	8	13	0.8	4	0	5
Colloid/Impermeant	–	Pentafraction Lactobionate Raffinose	Mannitol	–	Lactobionate Mannitol	Dextran 40	Dextran 40	Pentafraction Trehalose	Lactobionate Raffinose Polyethylene glycol
Buffer	Phosphate Bicarbonate	Phosphate	Histidine	Histidine	Histidine	Phosphate THAM	Phosphate	Phosphate	Phosphate
Antioxidant	–	Glutathione Allopurinol	Mannitol Tryptophan α-ketoglutarate	Tryptophan α-Ketoglutarate	Glutathione Mannitol	–	–	–	Glutathione Allopurinol
Glucose	180	–	–	–	–	5	10	–	–
Amino acids	–	–	Histidine Tryptophan	Histidine N-acetylhistidine Glycine Alanine Tryptophan Arginine Aspartate	Histidine Glutamic acid	–	–	–	–
Others Sulfate,	–	Sulfate Adenosine		– Deferoxamine LK 614	Sucrose	–	Sulfate	Sulfate Dibutyryl cAMP Gluconate	Nitroglycerin Adenosine
Reference	[41]	[41]	[38]	[38]	[41]	[43]	[48]	[49]	[41]

Note: Values are expressed in mmol/liter unless indicated otherwise.

developed for cardiac preservation, but it also achieved comparable patient survival for abdominal organ transplants[36,37]. Custodiol-N is a modified HTK solution with additional amino acids and chemicals. It is currently undergoing clinical trials; experimental studies showed promising reductions of hypoxic and cold-induced cell injury[38,39]. Celsior solution was originally made available in the 1990s as a heart preservation solution and was later also used for both thoracic and abdominal organ preservations[40]. Like HTK solution, Celsior solution also uses a histidine buffer and a low K^+ concentration. However, its Na^+ concentration is much higher. It shows equivalent performance to UW solution at a cheaper cost[41,42].

The risk of hyperkalemia-induced pulmonary vasoconstriction led to the development of extracellular fluid (ECF)-type solutions, which have lower K^+ and higher Na^+ concentrations[43]. In the 1980s, an ECF-type solution called EP4 (or EP-TU) was introduced, which sustained a canine lung preservation model for as long as 96 h[44]. A low-potassium dextran glucose (LPDG) solution was developed and currently used as the gold standard for lung preservation[43,45,46]. ET-K solution was developed by optimizing the properties of sugar and electrolyte contents and by adding a protective component for pulmonary endothelium, which showed excellent postoperative lung graft performance[47]. ET-K and EP-TU solutions have been applied in clinical lung transplantation in Japan[48,49]. Table 1 summarizes information regarding the composition of popular cold preservation solutions.

Ex vivo machine perfusion

IR-induced injury increases the risk of early graft dysfunction and reduces long-term survival after transplantation[50] (Figure 1). Meanwhile, the shortage of donor organs has led to the use of extended criteria donor (ECD) organs. Proper donor organ functional assessment and *ex vivo* repair/reconditioning of organs prior to transplantation has become necessary. Machine perfusion is a method involving organ perfusion with a controlled flow of perfusate. It facilitates the maintenance of organ microvasculature tone, provision of oxygen and nutrients in support of tissue metabolism, and removal of toxic metabolic waste.

The cellular rate of respiration is proportional to the surrounding temperature[51]. For example, SCS at 0–4 °C reduces the metabolic rate of the organ to approximately 5% of its physiological level[52,53]. Different temperatures have been investigated for *ex vivo* machine perfusion, including normothermic machine perfusion (NMP) at 35–38 °C, subnormothermic machine perfusion (SNMP) at 20–34 °C, controlled oxygenated rewarming (COR) at 8–20 °C, and hypothermic machine perfusion (HMP) at 0–8 °C (Figure 2) (Table 2).

Hypothermic machine perfusion

HMP (0–8 °C) is based on the concept that oxidative energy production by mitochondrial electron transport is sustained at hypothermic temperatures. HMP continuously provides metabolic substrates for the generation of ATP, which enables the graft to restore tissue energy. The first clinically available HMP device was developed by Folkert Belzer in 1960s[28] and used to perform the first HMP-preserved human kidney transplant in 1968[16]. Belzer *et al* achieved perfusion of the kidney with hypothermic, diluted plasma or blood for 3 days[28]. Humphries *et al* were able to extend kidney perfusion to 5 days[29].



Figure 1. Biological processes induced during ischemia-reperfusion that may lead to primary graft dysfunction.



Figure 2. Metabolic rate reduces with a decrease in temperature in humans. (SCS=static cold storage, HMP=hypothermic machine perfusion, COR=controlled oxygenated rewarming, SNMP=subnormothermic machine perfusion, and NMP=normothermic machine perfusion).

The 1990s saw the resurgence in interest in HMP for kidney preservation as both the demand for organs and reliance on ECD donors grew[54]. New HMP technology showed decreased rates of delayed graft function and improved outcomes in the case of marginal donors relative to SCS. By 2015, approximately 25% to 35% of all transplanted kidneys in the United States were preserved with HMP[54].

Challenges arise in the use of HMP for liver preservation since the liver receives blood from both the portal vein and hepatic artery[2]. However, the first clinical trial of HMP-preserved liver grafts showed shorter hospital stays and reduced vascular and biliary complications as benefits[55]. Few studies on HMP in heart and lung transplants have been reported. Nakajima *et al* reported that short-term HMP (1–2 h) can improve lung tissue energy levels and ameliorate IRI by decreasing the production of reactive oxygen species in rat lungs[56,57]. Michel *et al* showed that HMP preserved the cellular structure of donor hearts better than SCS during prolonged ischemic times in pigs[58]. Additional research in the field of cardiac and lung HMP is required.

Normothermic machine perfusion

NMP (35–38 °C) is a method of perfusing organs under physiologic conditions to maintain metabolic activity and viability. NMP maintains donor organs at body temperature while providing oxygen and essential substrates. Historically, NMP was developed to assess organ function prior to transplantation[59–61] and to preserve donor organs during distant procurement[62,63]. In 2001, Steen *et al* reintroduced the EVLP technique to evaluate lungs from donation after cardiac death (DCD)[64]. In 2007, they performed the first human transplantation of a rejected donor lung after assessment with EVLP[65]. Early studies were only able to achieve perfusion times of less than 6 h in large animal models[66,67]. In 2008, Cypel *et al* in Toronto modified the EVLP technique with low tidal volume ventilation, reduced perfusion rate and acellular perfusate, and extended

Table 2. Comparison of various methods used for preservation of organs.

Methods	Temperature	Organ	Merits	Challenge	Clinical application	Reference
Cold static storage	0–8 °C	Kidney, liver, lung, heart	Low cost, simple and easy to operate	Metabolite accumulation, not for organ function assessment	Kidney, liver, lung, heart	[32–50]
Hypothermic machine perfusion	0–8 °C	Kidney, liver, lung, heart	Provides oxygen and metabolic substrates	Perfusion time is limited, not for organ assessment	Kidney, liver	[28,29,54–58]
Normothermic machine perfusion	35–38 °C	Kidney, liver, lung, heart	Provides oxygen and essential substrates; maintains metabolic activity and viability; good for organ assessment and repair	Perfusion time is limited for organ regeneration	Kidney, liver, lung, heart	[8,10,64–78]
Subnormothermic machine perfusion	20–34 °C	Kidney, liver	Newly proposed technique	To be determined	–	[85–89]
Controlled oxygenated rewarming	8–20 °C	Kidney, Liver	Slowly, gradually rise the perfusate temperature to mitigate ischemia reperfusion injury	To be determined	Liver	[90–92]

perfusion time for up to 12 h in swine lungs with stable lung function[68]. The Toronto group conducted the first clinical trial successfully and reported excellent outcomes in 2011[69]. They further reported extended clinical outcome data[70,71], and the marginal donor lungs treated with EVLP showed comparable or even better results than regular lung transplants[72].

The success of EVLP inspired many research groups worldwide to further investigate the role of NMP in other organ systems. Nicholson *et al* described that a short period (1 or 2 h) of NMP could restore function and replenish ATP after warm and cold ischemia in porcine kidneys[8,73, 74]. The first clinical study on preserving kidney grafts with NMP was reported in 2011[75]. A follow-up clinical study showed that the delayed graft function rate was significantly lower in the NMP group than in the SCS group in ECD kidney transplantation[76]. The first clinical trial on NMP in liver transplantation was reported in 2016; 16 donations after brain death livers and 4 DCD livers were transplanted after NMP. The results showed that 30-day graft survival was similar between the NMP and SCS groups, and the median peak aspartate aminotransferase level was significantly lower in the NMP group than in the SCS group[77]. Clinical studies have shown promising results with NMP in resuscitating marginal and declined donor livers[9,78]. In addition, NMP has been shown to be superior to SCS in preserving DCD hearts in dogs[79]. In pigs, DCD hearts reconditioned with NMP showed comparable function to brain death donor hearts[80]. Over a 2-year period in a clinical trial involving 159 cases of orthotopic heart transplantation, NMP showed higher recipient survival and lower incidences of primary graft dysfunction (PGD) and acute rejection than SCS[10].

Several companies have now marketed a commercial portable machine to facilitate *ex vivo* machine perfusion, such as Organ Care System™ (TransMedics, USA) for the heart, lung, or liver and Organ Assist® device (Organ Assist, The Netherlands) for the lung, liver, or kidney. These devices can be used during organ transportation, which offers a platform for normothermic organ preservation immediately after procurement, monitoring and assessing graft function continuously[11,81]. These mobile devices have demonstrated encouraging results in clinical studies, which opens new avenues for organ preservation and transportation[82–84].

Subnormothermic machine perfusion

Subnormothermic machine perfusion (SNMP, 20–34 °C) is a midway approach between HMP and NMP[85]. Although better preservation times were accomplished with NMP than with HMP, it was speculated that the cytoprotective benefits of reduced cellular metabolism under hypothermic temperatures could further improve organ preservation. Meanwhile, sufficient metabolism would be maintained for viability assessment and organ repair/reconditioning[86]. Although studies have shown that livers or kidneys perfused with SNMP are superior to grafts preserved under SCS[87,88], a recent study showed that porcine kidneys preserved under SNMP were associated with higher indices of renal and tubular injury upon reperfusion than those preserved under NMP[89]. Therefore, whether SNMP should be developed in addition to NMP should be further determined.

Controlled oxygenated rewarming

Following cold ischemic preservation, the abrupt change in temperature from hypothermia to normothermia upon reperfusion may effectuate dysfunction of the mitochondria and pro-apoptotic signal transduction, which contributes to reperfusion-induced organ injury[90]. Hypothermic preservation is meant to protect the ischemic organ by reducing metabolism. However, ischemic redox dyshomeostasis leads to impairment of the mitochondrial membrane potential through mitochondrial transition pore opening. Mitochondrial damage can be further enhanced upon reperfusion[91]. COR (8–20 °C) is an alternative organ perfusion method involving a slow, gradual rise in the perfusate temperature. The period of COR is aimed to minimize injury to the graft and improve hepatocellular function upon reperfusion, offering gentle restitution of mitochondrial function[91]. Clinical studies have shown that COR is safely transferable to clinical practice in liver transplantation[91]. By the end of 2016, COR had been effectively applied in 15 human liver transplantations[92]. Minor and colleagues demonstrated that COR following SCS had better kidney function with mitigated activity of mitochondrial permeability transition pore opening, caspase 9 activation, and apoptosis in porcine kidneys[90]. It should be noted that during EVLP, lung perfusate was gradually warmed up during the first 30 min[68]. COR could be integrated into NMP.

Organ perfusate: from chemically defined solutions to blood/blood substitute

Perfusate composition is of central importance in maintaining stable organ function *ex vivo*. Blood-based perfusates were commonly used for organ perfusion before cell culture media were developed in the 1950s[93,94]. Due to its variable nature and associated technical and ethical concerns, the use of blood or blood products was gradually replaced by chemically defined solutions. For example, Steen Solution™, a chemically defined solution, has been widely used for EVLP and machine perfusion of other organs; it contains colloid components (human serum albumin and Dextran 40) to maintain oncotic pressure, physiological ion concentrations to regulate osmolality, and buffers to retain normal pH and glucose as an energy resource. However, the supplementation of additional nutrients, including red blood cells and other blood substitutes, to Steen Solution™ is under investigation to extend perfusion time.

Blood/blood substitutes

Studies have identified that blood-based perfusate is necessary during NMP to transport oxygen and meet metabolic demands, and it provides superior functional preservation in the case of kidney, liver and heart storage[95–98]. It is still disputed whether blood or red blood cells should be involved in EVLP. Some studies have highlighted the use of blood over acellular perfusates[99], whereas others have observed spontaneous lung injury when using whole blood[100]. When look-

ing over the studies that have currently achieved the longest perfusion times, it is interesting to see that perfusates used in these studies were either whole blood or blood-based solutions[95,101–104]. One study that provided pertinent evidence in support of the essentiality of blood in perfusate is a cross-circulation study. O'Neill *et al* connected a conventional EVLP circuit to the internal jugular vein of a recipient pig so that metabolic substrates and hormones from the recipient pig were available to the perfused lungs, whereas metabolic waste produced by the perfused lungs was cleared by the recipient; they effectively perfused the lungs with recipient autologous blood for 36 h without notable changes in physiological parameters[105].

However, the use of blood-based perfusate is accompanied by a series of concerns, such as immune-mediated responses, hemolysis, thrombus formation, biochemical and humoral variations, and a risk of blood-borne infectious transmission[106]. Further development of an acellular perfusate is another major direction.

Nutrients

Currently, commonly used perfusates, such as Steen solution™ and Organ Care System (OCS) perfusate, use glucose as the only energy resource. However, during NMP, organs are perfused at body temperature. Glucose alone is not sufficient for organ metabolism. To prolong NMP for organ repair, the incorporation of more nutrients, such as amino acids, vitamins, lipids and others, should be considered. Amino acids are basic components of proteins and are essential nutrients for cell survival and proliferation. Vitamins can help cells use the provided chemical energy to process proteins, carbohydrates, and fats required for cellular metabolism[107]. Amino acids and vitamins have been used routinely in cell culture media[93,94]. Interestingly, cell culture media were used for organ culture to maintain isolated organs for days without serum or blood supplements[27]. In liver and kidney studies, amino acids and extra glucose have been added into perfusate during NMP, and this approach showed promising results in pigs[108,109].

Fetal mouse lungs cultured in a medium without growth factors showed poorly developed airways and a lack of defined acinar structures[110], which suggests that growth factors and hormones may also be required for organ rebuilding /regeneration.

To avoid the use of human blood products, interest has increased in acellular oxygen carriers, which have similar oxygen carrying capacity to human hemoglobin[111]. Initial studies on hemoglobin-based oxygen carriers have shown encouraging results, including enhanced oxygenation and improved allograft function of *ex vivo* perfused organs in normothermic/subnormothermic conditions[106,112], which opens the door for blood substitution in future.

It is reasonable to conclude that an ideal perfusate should offer oxygen carrying capacity, oncotic properties, buffers to maintain physiological pH, metabolic substrates and physiological electrolyte levels, growth factors and hormones. A blood substitute designed to replace human blood in *ex vivo* machine perfusion will be a promising direction for prolonging the preservation of isolated organs.

Future perspectives: organ repair/reprogramming with *ex vivo* machine perfusion

Prolonged *ex vivo* machine perfusion & organ repair/reprogramming

The incredible progress of organ preservation research over the past few decades has led to the booming success of clinical organ transplantation as a treatment for patients with end-stage disease. However, this demand has skyrocketed to a level that cannot be satisfied by the number of available donor organs. The use of *ex vivo* machine perfusion aspires to warranting the use of marginal donors by minimizing IRI and facilitating the repair/regeneration of suboptimal grafts in order to expand the donor pool and improve overall graft function after transplantation. For this purpose, prolonged *ex vivo* perfusion time is required (Figure 3).

Organ repair

There has been an increasing number of studies focusing on the application of *ex vivo* machine perfusion for organ repair. EVLP is among the most active areas of study. A series of therapeutic strategies have been studied using EVLP for lung repair. For example, different drugs were delivered through perfusate to mitigate IRI[113–115], therapeutic gases (NO, CO, H_2) were inhaled during EVLP to reduce inflammatory response and lung edema[116–118], mesenchymal stem cells were used to treat lung injury induced by endotoxins and infection[119], and IL-10 gene therapy was developed to prevent IRI[120,121]. When the types of injury are clear, injury-specific treatments can be used during EVLP. For example, high-dose, broad-spectrum anti-microbial agents were added to perfusate to treat human



Figure 3. The advantage of the potential use of normothermic machine perfusion.

donor lung infection[122,123], lung lavage and surfactant replacement were used to treat acid aspiration-induced pig lung injury[124–126], and pulmonary thrombolysis was performed to eliminate pulmonary embolism followed by successful lung transplantation[127,128].

In kidney, Brasile *et al* delivered heme analog cobalt protoporphyrin during *ex vivo* kidney perfusion to reduce inflammatory and free radical injury by upregulating the protective gene hemoxygenase-1 in canines[129]. They also used growth factors to upregulate cellular processes to resuscitate and repair warm IRI in canines and in rejected human kidneys[130]. Hosgood *et al* delivered nitric oxide donors and carbon monoxide-releasing molecules during NMP, which enhanced renal flow and improved renal function in pigs[131]. Yang *et al* investigated the effect of adding erythropoietin to perfusate during NMP and found that erythropoietin promoted inflammatory cell apoptosis and drived inflammatory and apoptotic cells into tubular lumens, which led to inflammation clearance, renal protection, and tissue remodeling in a porcine model[132].

In liver, studies on therapeutic medications during NMP to reduce IRI showed promising results in pigs and rats[133–135]. Goldaracena *et al* delivered an antiviral drug to perfusate during normothermic *ex vivo* liver perfusion and effectively induced Hepatitis C virus resistance after pig liver transplantation[136].

Organ regeneration

In 2008, Ott *et al* reported the first whole organ engineering success. They used *ex vivo* machine perfusion as a platform, decellularized rat hearts by coronary perfusion with detergents in a Langendorff apparatus, then reseeded these constructs by perfusion with cardiac or endothelial cells; eight constructs were maintained for up to 28 days by coronary perfusion with a nutrient-rich medium in a bioreactor that simulated cardiac physiology. This study revolutionized the field of tissue engineering, kindled hope for possibility of whole organ engineering[137]. They also successfully created bioartificial rat lungs using a slightly modified approach and subsequently transplanted the regenerated left lungs orthotopically. The bioartificial lungs provided gas exchange *in vivo* for up to 6 h after extubation[138]. Using the same perfusion system, Ott's group further maintained the bioartificial rat lungs for up to 7 days with good function after implantation[139]. They later decellularized human and porcine lungs[140], which brought the matrix to clinical scale. A similar perfusion method has also been used to create kidney and liver scaffolds in animals and in clinically rejected human organs[141]. Although there are still many challenges, the use of NMP alongside stem cells for organ engineering has received increasing interest.

Organ immunomodulation

Ex vivo machine perfusion has also provided a potential platform for organ immunomodulation. Miyoshi *et al* reported that *ex vivo* perfusion of canine pancreaticoduodenal allografts using class-II-specific monoclonal antibodies delays the onset of acute rejection[142]. Brasile *et al* treated canine kidney grafts with a bioengineered interface consisting of a nano-barrier membrane during NMP for 3 h. They found that untreated control dogs experienced a mean onset of rejection on day 6, whereas the mean onset of rejection was significantly delayed until day 30 in dogs in the treatment group[143]. Martens *et al* distributed multipotent adult progenitor cells in the airway during EVLP and observed a reduction in pro-inflammatory cytokines and neutrophils in bronchoalveolar lavage fluid, which is related to innate immune system modulation and may play an important role in reducing PGD after transplantation[144].

Due to severe donor shortage from humans, xenotransplantation is gaining more attention. *Ex vivo* perfusion of porcine lungs with fresh human blood is used to study discordant pulmonary xenograft injury[145,146]. Pre-perfusion of donor organs with recipient serum[147] and the delivery of targeted drugs have been attempted to prevent hyperacute rejection[148]. *Ex vivo* machine perfusion offers an effective platform to alleviate discordant xenograft rejection by removing the recipient's xenoreactive natural antibodies[149]. Studies on the recellularization of animal organ scaffolds by human liver stem/progenitor cells with *ex vivo* machine perfusion techniques are under investigation[150,151].

Conclusion

Since the very first speculation on organ preservation made by Cesar Julien Jean Le Gallois over two centuries ago, tremendous progress has been made in this field of research. In the early days, organs were perfused with blood at physiological temperatures. The introduction of SCS in the 1960s revolutionized organ preservation. From then on, it became standard practice to statically preserve organs at hypothermic temperatures. With the recent demand to expand the organ donor pool, the currently accepted status of organ preservation is seeing a retrospective shift from SCS to theories inspired by early techniques, as these techniques provide great potential for improved graft preservation, viability assessment, and most importantly, repair/regeneration. The success of organ preservation with dynamic machine perfusion operating on the basis of blood-based perfusates at close-to-physiological temperatures has prompted further in-depth studies on organ preservation and repair/reconditioning. The need to prolong *ex vivo* machine perfusion time requires the optimization of current perfusates with the addition of essential components to meet metabolic needs. Prolonged *ex vivo* machine perfusion opens a door for organ repair and reprogramming, warranting further investigation of novel strategies to improve donor graft quality prior to transplantation.

Acknowledgements

Lei JING is a PhD candidate of the First Bethune Hospital of Jilin University and is supervised by Dr Li-ping PENG; she is supported by the First Bethune Hospital of Jilin University. This work was supported by research grants from the Canadian Institutes of Health Research (MOP-42546, MOP-119514, and PJT-148847) and an Ontario Research Fund-Research

Excellence award.

References

1 Southard J, Belzer F. Organ preservation. Annu Rev Med 1995; 46: 235–47.
2 Guibert EE, Petrenko AY, Balaban CL, Somov AY, Rodriguez J V, Fuller BJ. Organ preservation: current concepts and new strategies for the next decade. Transfus Med Hemother 2011: 125–42.
3 Catena F, Coccolini F, Montori G, Vallicelli C, Amaduzzi A, Ercolani G, *et al*. Kidney preservation: review of present and future perspective. Transplant Proc 2013; 45: 3170–7.
4 Liu WP, Humphries AL, Russell R, Stoddard LD, Moretz WH, Moretz WH. 48-hour storage of canine kidneys after brief perfusion with Collins' solution. Ann Surg 1971; 173: 748–57.
5 Wierup P, Haraldsson A, Nilsson F, Pierre L, Scherstén H, Silverborn M, *et al*. *Ex vivo* evaluation of nonacceptable donor lungs. Ann Thorac Surg 2006; 81: 460–6.
6 Gao X, Liu W, Liu M. *Ex vivo* lung perfusion: scientific research and clinical application. Pract J Organ Transplant 2017; 5: 177–87.
7 Cypel M, Keshavjee S. The clinical potential of *ex vivo* lung perfusion. Expert Rev Respir Med 2012; 6: 27–35.
8 Hosgood SA, Barlow AD, Yates PJ, Snoeijs MGJ, Van Heurn EL, Nicholson ML. A pilot study assessing the feasibility of a short period of normothermic preservation in an experimental model of non heart beating donor kidneys. J Surg Res 2011; 171: 283–90.
9 Perera T, Mergental H, Stephenson B, Roll GR, Cilliers H, Liang R, *et al*. First human liver transplantation using a marginal allograft resuscitated by normothermic machine perfusion. Liver Transpl 2016; 22: 120–4.
10 Koerner MM, Ghodsizad A, Schulz U, Banayosy A El, Koerfer R, Tenderich G. Normothermic *ex vivo* allograft blood perfusion in clinical heart transplantation. Heart Surg Forum 2014; 17: E141–5.
11 Van Raemdonck D, Neyrinck A, Rega F, Devos T, Pirenne J. Machine perfusion in organ transplantation: a tool for *ex-vivo* graft conditioning with mesenchymal stem cells? Curr Opin Organ Transpl 2013; 18: 24–33.
12 Mariscal A, Cypel M, Keshavjee S. *Ex vivo* lung perfusion: a key tool for translational science in the lungs. Curr Transplant Reports 2017; 4: 149–58.
13 Hosgood SA, Van Heurn E, Nicholson ML. Normothermic machine perfusion of the kidney: better conditioning and repair? Transpl Int 2015; 28: 657–64.
14 Selten J, Schlegel A, de Jonge J, Dutkowski P. Hypo- and normothermic perfusion of the liver: which way to go? Best Pract Res Clin Gastroenterol 2017: 171–9.
15 Collins GM, Bravo-Shugarman M, Terasaki PI. Kidney preservation for transportation: initial perfusion and 30 hours' ice storage. Lancet 1969; 294: 1219–22.
16 Belzer FO, Ashby BS, Gulyassy PF, Powell M. Successful seventeen-hour preservation and transplantation of human-cadaver kidney. N Engl J Med 1968; 278: 608–10.
17 Brettschneider L, Daloze PM, Huguet C, Porter KA, Groth CG, Kashiwagi N, *et al*. The use of combined preservation techniques for extended storage of orthotopic liver homografts. Surg Gynecol Obstet 1968; 126: 263–74.
18 Le Gallois M. Experiments on the principle of life, and particularly on the principle of the motions of the heart, and on the seat of this principle: including the report made to the first class of the Institute, upon the experiments relative to the mtions of the heart, Philadelphia: M Thomas; 1813.
19 Boettcher W, Merkle F, Weitkemper HH. History of extracorporeal circulation: the conceptional and developmental period. J Extra Corpor Technol 2003; 35: 172–83.
20 Okiljević B, Šušak S, Redžek A, Rosić M, Velicki L. Development of cardiopulmonary bypass–a historical review. Srp Arh Celok Lek 2016; 144: 670–5.
21 Embley E, Martin C. The action of anaesthetic quantities of chloroform upon the blood vessels of the bowel and kidney; with an account of an artificial circulation apparatus. J Physiol 1905; 32: 147–58.
22 Daly I de B, Thorpe WV. An isolated mammalian heart preparation capable of performing work for prolonged periods. J Physiol 1933; 79: 199–217.
23 Trowell OA. The histology of the isolated perfused lung. Q J Exp Physiol Cogn Med Sci 1943; 32: 203–12.
24 Veith FJ, Hagstrom JW, Nehlsen SL, Karl RC, Deysine M. Functional, hemodynamic, and anatomic changes in isolated perfused dog lungs: the importance of perfusate characteristics. Ann Surg 1967; 165: 267–78.
25 Brodie TG. The perfusion of surviving organs. J Physiol 1903; 29: 266–75.
26 Carrel A. The culture of whole organs: I. technique of the culture of the thyroid gland. J Exp Med 1937; 65: 515–26.
27 Hou LT, Ewen SW, Beck JS. Histological, metabolic and histochemical studies on normal human placenta in organ culture. Br J Exp Pathol 1968; 49: 648–57.
28 Belzer FO, Ashby BS, Dunphy JE. 24-hour and 72-hour preservation of canine kidneys. Lancet 1967; 2: 536–8.
29 Humphries AL, Russell R, Stoddard LD, Moretz WH. Successful five-day kidney preservation. Perfusion with hypothermic, diluted plasma. Invest Urol 1968; 5: 609–18.
30 Calne RY, Pegg DE, Pryse-Davies J, Brown FL. Renal preservation by ice-cooling: an experimental study relating to kidney transplantation from cadavers. Br Med J 1963; 2: 651–5.
31 Collins GM, Bravo-Shugarman M, Terasaki PI, Braf Z, Sheil AG, Williams G. Kidney preservation for transportation. IV. eight-thousand-mile international air transport. Aust N Z J Surg 1970; 40: 195–7.
32 Aydin G, Okiye SE, Zincke H. Successful 24-hour preservation of the ischemic canine kidney with Euro-Collins solution. J Urol 1982; 128: 1401–3.
33 Wahlberg JA, Southard JH, Belzer FO. Development of a cold storage solution for pancreas preservation. Cryobiology 1986; 23: 477–82.
34 Jamieson RW, Friend PJ. Organ reperfusion and preservation. Front Biosci 2008; 13: 221–35.
35 Okada Y, Kondo T. Preservation solution for lung transplantation. Gen Thorac Cardiovasc Surg 2009; 57: 635–9.
36 Schneeberger S, Biebl M, Steurer W, Hesse UJ, Troisi R, Langrehr JM, *et al*. A prospective randomized multicenter trial comparing histidine-tryptophane-ketoglutarate versus University of Wisconsin perfusion solution in clinical pancreas transplantation. Transpl Int 2009; 22: 217–24.
37 Moray G, Sevmis S, Karakayali FY, Gorur SK, Haberal M. Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin in living-donor liver transplantation. Transplant Proc 2006; 38: 3572–5.
38 Loganathan S, Radovits T, Hirschberg K, Korkmaz S, Koch A, Karck M, *et al*. Effects of Custodiol-N, a novel organ preservation solution, on ischemia/reperfusion injury. J Thorac Cardiovasc Surg 2010; 139: 1048–56.
39 Pizanis N, Petrov A, Heckmann J, Wiswedel I, Wohlschläger J, de Groot H, *et al*. A new preservation solution for lung transplantation:

evaluation in a porcine transplantation model. J Hear Lung Transplant 2012; 31: 310–7.
40 Karam G, Compagnon P, Hourmant M, Despins P, Duveau D, Noury D, *et al*. A single solution for multiple organ procurement and preservation. Transpl Int 2005; 18: 657–63.
41 Voigt MR, DeLario GT. Perspectives on abdominal organ preservation solutions: a comparative literature review. Prog Transplant 2013; 23: 383–91.
42 O'Callaghan JM, Morgan RD, Knight SR, Morris PJ. The effect of preservation solutions for storage of liver allografts on transplant outcomes. Ann Surg 2014; 260: 46–55.
43 Latchana N, Peck JR, Whitson B, Black SM. Preservation solutions for cardiac and pulmonary donor grafts: a review of the current literature. J Thorac Dis 2014; 6: 1143–9.
44 Handa M, Fujimura S, Kondo T, Ichinose T, Shiraishi Y, Nakada T. A study of preservation solution for 48- and 96-hour simple hypothermic storage of canine lung transplants. Tohoku J Exp Med 1989; 159: 205–14.
45 Keshavjee SH, Yamazaki F, Cardoso PF, McRitchie DI, Patterson GA, Cooper JD. A method for safe twelve-hour pulmonary preservation. J Thorac Cardiovasc Surg 1989; 98: 529–34.
46 Date H, Matsumura A, Manchester JK, Obo H, Lima O, Cooper JM, *et al*. Evaluation of lung metabolism during successful twenty-four-hour canine lung preservation. J Thorac Cardiovasc Surg 1993; 105: 480–91.
47 Ikeda M, Bando T, Yamada T, Sato M, Menjyu T, Aoyama A, *et al*. Clinical application of ET-Kyoto solution for lung transplantation. Surg Today 2015; 45: 439–43.
48 Okada Y, Matsumura Y, Date H, Bando T, Oto T, Sado T, *et al*. Clinical application of an extracellular phosphate-buffered solution (EP-TU) for lung preservation: preliminary results of a Japanese series. Surg Today 2012; 42: 152–6.
49 Omasa M, Hasegawa S, Bando T, Hanaoka N, Yoshimura T, Nakamura T, *et al*. Application of ET-Kyoto solution in clinical lung transplantation. Ann Thorac Surg 2004; 77: 338–9.
50 Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med 2011; 17: 1391–401.
51 Robinson WR, Peters RH, Zimmermann J. The effects of body size and temperature on metabolic rate of organisms. Can J Zool 1983; 61: 281–8.
52 de Perrot M, Bonser RS, Dark J, Kelly RF, McGiffin D, Menza R, *et al*. Report of the ISHLT working group on primary lung graft dysfunction part III: donor-related risk factors and markers. J Heart Lung Transplant 2005; 24: 1460–7.
53 Weeder PD, van Rijn R, Porte RJ. Machine perfusion in liver transplantation as a tool to prevent non-anastomotic biliary strictures: rationale, current evidence and future directions. J Hepatol 2015; 63: 265–75.
54 Henry SD, Guarrera J V. Protective effects of hypothermic *ex vivo* perfusion on ischemia/reperfusion injury and transplant outcomes. Transplant Rev 2012; 26: 163–75.
55 Guarrera J V, Henry SD, Samstein B, Odeh-Ramadan R, Kinkhabwala M, Goldstein MJ, *et al*. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant 2010; 10: 372–81.
56 Nakajima D, Chen F, Yamada T, Sakamoto J, Osumi A, Fujinaga T, *et al*. Hypothermic machine perfusion ameliorates ischemia-reperfusion injury in rat lungs from non-heart-beating donors. Transplantation 2011; 92: 858–63.
57 Nakajima D, Chen F, Okita K, Motoyama H, Hijiya K, Ohsumi A, *et al*. Reconditioning lungs donated after cardiac death using short-term hypothermic machine perfusion. Transplant J 2012; 94: 999–1004.
58 Michel SG, LaMuraglia II GM, Madariaga MLL, Titus JS, Selig MK, Farkash EA, *et al*. Twelve-hour hypothermic machine perfusion for donor heart preservation leads to improved ultrastructural characteristics compared to conventional cold storage. Ann Transplant 2015; 20: 461–8.
59 Jirsch DW, Fisk RL, Couves CM. *Ex vivo* evaluation of stored lungs. Ann Thorac Surg 1970; 10: 163–8.
60 Carter JN, Green RD, Halasz NA, Collins GM. *Ex vivo* perfusion: a renal preservation model. J Surg Res 1981; 31: 55–60.
61 Fukuzawa K, Shimada M, Takenaka K, Sugimachi K. *Ex vivo* perfusion for accurate assessment of liver graft viability in dogs. J Invest Surg 1990; 3: 261–6.
62 Hardesty RL, Griffith BP. Autoperfusion of the heart and lungs for preservation during distant procurement. J Thorac Cardiovasc Surg 1987; 93: 11–8.
63 Kontos GJ Jr, Borkon AM, Adachi H, Baumgartner WA, Hutchins GM, Brawn J, *et al*. Successful extended cardiopulmonary preservation in the autoperfused working heart-lung preparation. Surgery 1987; 102: 269–76.
64 Steen S, Sjöberg T, Pierre L, Liao Q, Eriksson L, Algotsson L. Transplantation of lungs from a non-heart-beating donor. Lancet 2001; 357: 825–9.
65 Steen S, Ingemansson R, Eriksson L, Pierre L, Algotsson L, Wierup P, *et al*. First human transplantation of a nonacceptable donor lung after reconditioning *ex vivo*. Ann Thorac Surg 2007; 83: 2191–4.
66 Steen S, Liao Q, Wierup PN, Bolys R, Pierre L, Sjöberg T. Transplantation of lungs from non-heart-beating donors after functional assessment *ex vivo*. Ann Thorac Surg 2003; 76: 244–52; discussion 252.
67 Erasmus ME, Fernhout MH, Elstrodt JM, Rakhorst G. Normothermic *ex vivo* lung perfusion of non-heart-beating donor lungs in pigs: from pretransplant function analysis towards a 6-h machine preservation. Transpl Int 2006; 19: 589–93.
68 Cypel M, Yeung JC, Hirayama S, Rubacha M, Fischer S, Anraku M, *et al*. Technique for prolonged normothermic *ex vivo* lung perfusion. J Hear Lung Transpl 2008; 27: 1319–25.
69 Cypel M, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, *et al*. Normothermic *ex vivo* lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364: 1431–40.
70 Cypel M, Yeung JC, Machuca T, Chen M, Singer LG, Yasufuku K, *et al*. Experience with the first 50 *ex vivo* lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg 2012; 144: 1200–7.
71 Tikkanen JM, Cypel M, Machuca TN, Azad S, Binnie M, Chow CW, *et al*. Functional outcomes and quality of life after normothermic *ex vivo* lung perfusion lung transplantation. J Heart Lung Transplant 2015; 34: 547–56.
72 Machuca TN, Mercier O, Collaud S, Tikkanen J, Krueger T, Yeung JC, *et al*. Lung transplantation with donation after circulatory determination of death donors and the impact of *ex vivo* lung perfusion. Am J Transplant 2015; 15: 993–1002.
73 Bagul A, Hosgood SA, Kaushik M, Kay MD, Waller HL, Nicholson ML. Experimental renal preservation by normothermic resuscitation perfusion with autologous blood. Br J Surg 2008; 95: 111–8.
74 Hosgood SA, Patel M, Nicholson ML. The conditioning effect of *ex vivo* normothermic perfusion in an experimental kidney model. J Surg Res 2013; 182: 153–60.
75 Hosgood SA, Nicholson ML. First in man renal transplantation after *ex vivo* normothermic perfusion. Transplantation 2011; 92: 735–8.
76 Nicholson ML, Hosgood SA. Renal transplantation after *ex vivo* normothermic perfusion: the first clinical study. Am J Transplant

2013; 13: 1246–52.
77 Ravikumar R, Jassem W, Mergental H, Heaton N, Mirza D, Perera MTPR, *et al*. Liver transplantation after *ex vivo* normothermic machine preservation: a phase 1 (first-in-man) clinical trial. Am J Transplant 2016; 16: 1779–87.
78 Mergental H, Perera MTPR, Laing RW, Muiesan P, Isaac JR, Smith A, *et al*. Transplantation of declined liver allografts following normothermic ex-situ evaluation. Am J Transplant 2016; 16: 3235–45.
79 Repse S, Pepe S, Anderson J, McLean C, Rosenfeldt FL, Shimizu N. Cardiac reanimation for donor heart transplantation after cardiocirculatory death. J Heart Lung Transplant 2010; 29: 747–55.
80 Ali AA, White P, Xiang B, Lin HY, Tsui SS, Ashley E, *et al*. Hearts from DCD donors display acceptable biventricular function after heart transplantation in pigs. Am J Transplant 2011; 11: 1621–32.
81 Van Raemdonck D, Neyrinck A, Cypel M, Keshavjee S. *Ex-vivo* lung perfusion. Transpl Int 2015; 28: 643–56.
82 Ardehali A, Esmailian F, Deng M, Soltesz E, Hsich E, Naka Y, *et al*. *Ex-vivo* perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet 2015; 385: 2577–84.
83 Zeriouh M, Sabashnikov A, Mohite PN, Zych B, Patil NP, García-Sáez D, *et al*. Utilization of the organ care system for bilateral lung transplantation: preliminary results of a comparative study. Interact Cardiovasc Thorac Surg 2016; 23: 351–7.
84 op den Dries S, Karimian N, Sutton ME, Westerkamp AC, Nijsten MWN, Gouw ASH, *et al*. *Ex vivo* normothermic machine perfusion and viability testing of discarded human donor livers. Am J Transplant 2013; 13: 1327–35.
85 Berendsen TA, Bruinsma BG, Lee J, D'Andrea V, Liu Q, Izamis ML, *et al*. A simplified subnormothermic machine perfusion system restores ischemically damaged liver grafts in a rat model of orthotopic liver transplantation. Transplant Res 2012; 1: 6.
86 Bejaoui M, Pantazi E, Folch-Puy E, Baptista PM, García-Gil A, Adam R, *et al*. Emerging concepts in liver graft preservation. World J Gastroenterol 2015; 21: 396–407.
87 Tolboom H, Izamis ML, Sharma N, Milwid JM, Uygun B, Berthiaume F, *et al*. Subnormothermic machine perfusion at both 20 °C and 30 °C recovers ischemic rat livers for successful transplantation. J Surg Res 2012; 175: 149–56.
88 Hoyer DP, Gallinat A, Swoboda S, Wohlschläger J, Rauen U, Paul A, *et al*. Subnormothermic machine perfusion for preservation of porcine kidneys in a donation after circulatory death model. Transpl Int 2014; 27: 1097–106.
89 Adams TD, Patel M, Hosgood SA, Nicholson ML. Lowering perfusate temperature from 37 °C to 32 °C diminishes function in a porcine model of *ex vivo* kidney perfusion. Transplant Direct 2017; 3: e140.
90 Schopp I, Reissberg E, Lüer B, Efferz P, Minor T. Controlled rewarming after hypothermia: adding a new principle to renal preservation. Clin Transl Sci 2015; 8: 475–8.
91 Hoyer DP, Mathé Z, Gallinat A, Canbay AC, Treckmann JW, Rauen U, *et al*. Controlled oxygenated rewarming of cold stored livers prior to transplantation. Transplantation 2016; 100: 147–52.
92 Hoyer DP, Paul A, Minor T. Prediction of hepatocellular preservation injury immediately before human liver transplantation by controlled oxygenated rewarming. Transplant Direct 2017; 3: e122.
93 EAGLE H. Nutrition needs of mammalian cells in tissue culture. Science 1955; 122: 501–14.
94 EAGLE H. The specific amino acid requirements of a mammalian cell (strain L) in tissue culture. J Biol Chem 1955; 214: 839–52.
95 Liu Q, Nassar A, Farias K, Buccini L, Mangino MJ, Baldwin W, *et al*. Comparing normothermic machine perfusion preservation with different perfusates on porcine livers from donors after circulatory death. Am J Transplant 2016; 16: 794–807.
96 Höchel J, Lehmann D, Fehrenberg C, Unger V, Groneberg DA, Grosse-Siestrup C. Effects of different perfusates on functional parameters of isolated perfused dog kidneys. Nephrol Dial Transplant 2003; 18: 1748–54.
97 Podesser BK, Hallström S, Schima H, Huber L, Weisser J, Kröner A, *et al*. The erythrocyte-perfused "working heart" model: hemodynamic and metabolic performance in comparison to crystalloid perfused hearts. J Pharmacol Toxicol Methods 1999; 41: 9–15.
98 White CW, Hasanally D, Mundt P, Li Y, Xiang B, Klein J, *et al*. A whole blood-based perfusate provides superior preservation of myocardial function during *ex vivo* heart perfusion. J Heart Lung Transplant 2015; 34: 113–21.
99 Kraft SA, Fujishima S, McGuire GP, Thompson JS, Raffin TA, Pearl RG. Effect of blood and albumin on pulmonary hypertension and edema in perfused rabbit lungs. J Appl Physiol 1995; 78: 499–504.
100 Pearse DB, Sylvester JT. Spontaneous injury in isolated sheep lungs: role of resident polymorphonuclear leukocytes. J Appl Physiol 1992; 72: 2475–81.
101 Loor G, Howard BT, Spratt JR, Mattison LM, Panoskaltsis-Mortari A, Brown RZ, *et al*. Prolonged EVLP using OCS lung: cellular and acellular perfusates. Transplantation 2017; 101: 2303–11.
102 Spratt JR, Mattison LM, Iaizzo PA, Brown RZ, Helms H, Iles TL, *et al*. An experimental study of the recovery of injured porcine lungs with prolonged normothermic cellular *ex vivo* lung perfusion following donation after circulatory death. Transpl Int 2017;30:932–44.
103 Kaths JM, Cen JY, Chun YM, Echeverri J, Linares I, Ganesh S, *et al*. Continuous normothermic *ex vivo* kidney perfusion is superior to brief normothermic perfusion following static cold storage in donation after circulatory death pig kidney transplantation. Am J Transplant 2017; 17: 957–69.
104 Trahanas JM, Witer LJ, Alghanem F, Bryner BS, Iyengar A, Hirschl JR, *et al*. Achieving 12 hour normothermic ex situ heart perfusion. ASAIO J 2016; 62: 470–6.
105 O'Neill JD, Guenthart BA, Kim J, Chicotka S, Queen D, Fung K, *et al*. Cross-circulation for extracorporeal support and recovery of the lung. Nat Biomed Eng 2017; 1: 37.
106 Laing RW, Bhogal RH, Wallace L, Boteon Y, Neil DAH, Smith A, *et al*. The use of an acellular oxygen carrier in a human liver model of normothermic machine perfusion. Transplantation 2017; 101: 2746–56.
107 Bender DA. Nutritional biochemistry of the vitamins. Cambridge: cambridge University Press; 2003.
108 Kaths JM, Echeverri J, Goldaracena N, Louis KS, Chun YM, Linares I, *et al*. Eight-hour continuous normothermic *ex vivo* kidney perfusion is a safe preservation technique for kidney transplantation: a new opportunity for the storage, assessment, and repair of kidney grafts. Transplantation 2016; 100: 1862–70.
109 Zhang Z-B, Gao W, Liu L, Shi Y, Ma N, Shen ZY. Development and assessment of normothermic machine perfusion preservation for extracorporeal splitting of pig liver. Ann Transplant 2017; 22: 507–17.
110 Chinoy MR, Zgleszewski SE, Cilley RE, Blewett CJ, Krummel TM, Reisher SR, *et al*. Influence of epidermal growth factor and transforming growth factor beta-1 on patterns of fetal mouse lung branching morphogenesis in organ culture. Pediatr Pulmonol 1998; 25: 244–56.
111 Kocian R, Spahn DR. Haemoglobin, oxygen carriers and perioperative organ perfusion. Best Pract Res Clin Anaesthesiol 2008; 22: 63–80.

112 Fontes P, Lopez R, van der Plaats A, Vodovotz Y, Minervini M, Scott V, *et al*. Liver preservation with machine perfusion and a newly developed cell-free oxygen carrier solution under subnormothermic conditions. Am J Transplant 2015; 15: 381–94.
113 Wagner CE, Pope NH, Charles EJ, Huerter ME, Sharma AK, Salmon MD, *et al*. *Ex vivo* lung perfusion with adenosine A2A receptor agonist allows prolonged cold preservation of lungs donated after cardiac death. J Thorac Cardiovasc Surg 2016; 151: 538–46.
114 Huerter ME, Sharma AK, Zhao Y, Charles EJ, Kron IL, Laubach VE. Attenuation of pulmonary ischemia-reperfusion injury by adenosine A2B receptor antagonism. Ann Thorac Surg 2016; 102: 385–93.
115 Martens A, Boada M, Vanaudenaerde BM, Verleden SE, Vos R, Verleden GM, *et al*. Steroids can reduce warm ischemic reperfusion injury in a porcine donation after circulatory death model with *ex vivo* lung perfusion evaluation. Transpl Int 2016; 29: 1237–46.
116 Dong BM, Abano JB, Egan TM. Nitric oxide ventilation of rat lungs from non-heart-beating donors improves posttransplant function. Am J Transplant 2009; 9: 2707–15.
117 Dong B, Stewart PW, Egan TM. Postmortem and *ex vivo* carbon monoxide ventilation reduces injury in rat lungs transplanted from non-heart-beating donors. J Thorac Cardiovasc Surg 2013; 146: 429–36.e1.
118 Noda K, Shigemura N, Tanaka Y, Bhama J, D'Cunha J, Kobayashi H, *et al*. Hydrogen preconditioning during *ex vivo* lung perfusion improves the quality of lung grafts in rats. Transplantation 2014; 98: 499–506.
119 Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in *ex vivo* human lungs injured with live bacteria. Am J Respir Crit Care Med 2013; 187: 751–60.
120 Cypel M, Liu M, Rubacha M, Yeung JC, Hirayama S, Anraku M, *et al*. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1: 4ra9.
121 Machuca TN, Cypel M, Bonato R, Yeung JC, Chun Y-M, Juvet S, *et al*. Safety and efficacy of *ex vivo* donor lung adenoviral IL-10 gene therapy in a large animal lung transplant survival model. Hum Gene Ther 2017; 28: 757–65.
122 Andreasson A, Karamanou DM, Perry JD, Perry A, Özalp F, Butt T, *et al*. The effect of *ex vivo* lung perfusion on microbial load in human donor lungs. J Hear Lung Transplant 2014; 33: 910–6.
123 Nakajima D, Cypel M, Bonato R, Machuca TN, Iskender I, Hashimoto K, *et al*. *Ex vivo* perfusion treatment of infection in human donor lungs. Am J Transplant 2016; 16: 1229–37.
124 Inci I, Hillinger S, Arni S, Kaplan T, Inci D, Weder W. Reconditioning of an injured lung graft with intrabronchial surfactant instillation in an *ex vivo* lung perfusion system followed by transplantation. J Surg Res 2013; 184: 1143–9.
125 Khalifé-Hocquemiller T, Sage E, Dorfmuller P, Mussot S, Le Houérou D, Eddahibi S, *et al*. Exogenous surfactant attenuates lung injury from gastric-acid aspiration during *ex vivo* reconditioning in pigs. Transplant J 2014;97:413–8.
126 Nakajima D, Liu M, Ohsumi A, Kalaf R, Iskender I, Hsin M, *et al*. Lung lavage and surfactant replacement during *ex vivo* lung perfusion for treatment of gastric acid aspiration-induced donor lung injury. J Heart Lung Transplant 2017; 36: 577–85.
127 Machuca TN, Hsin MK, Ott HC, Chen M, Hwang DM, Cypel M, *et al*. Injury-specific *ex vivo* treatment of the donor lung: pulmonary thrombolysis followed by successful lung transplantation. Am J Respir Crit Care Med 2013; 188: 878–80.
128 Inci I, Yamada Y, Hillinger S, Jungraithmayr W, Trinkwitz M, Weder W. Successful lung transplantation after donor lung reconditioning with urokinase in *ex vivo* lung perfusion system. Ann Thorac Surg 2014; 98: 1837–8.
129 Brasile L, Buelow R, Stubenitsky BM, Kootstra G. Induction of heme oxygenase-1 in kidneys during *ex vivo* warm perfusion. Transplantation 2003; 76: 1145–9.
130 Brasile L, Stubenitsky BM, Haisch CE, Kon M, Kootstra G. Repair of damaged organs *in vitro*. Am J Transplant 2005; 5: 300–6.
131 Hosgood SA, Bagul A, Kaushik M, Rimoldi J, Gadepalli RS, Nicholson ML. Application of nitric oxide and carbon monoxide in a model of renal preservation. Br J Surg 2008; 95: 1060–7.
132 Yang B, Hosgood SA, Bagul A, Waller HL, Nicholson ML. Erythropoietin regulates apoptosis, inflammation and tissue remodelling via caspase-3 and IL-1β in isolated hemoperfused kidneys. Eur J Pharmacol 2011; 660: 420–30.
133 Monbaliu D, Vekemans K, Hoekstra H, Vaahtera L, Libbrecht L, Derveaux K, *et al*. Multifactorial biological modulation of warm ischemia reperfusion injury in liver transplantation from non-heart-beating donors eliminates primary nonfunction and reduces bile salt toxicity. Ann Surg 2009; 250: 808–17.
134 Maida K, Akamatsu Y, Hara Y, Tokodai K, Miyagi S, Kashiwadate T, *et al*. Short oxygenated warm perfusion with prostaglandin E1 administration before cold preservation as a novel resuscitation method for liver grafts from donors after cardiac death in a rat *in vivo* model. Transplantation 2016; 100: 1052–8.
135 Goldaracena N, Echeverri J, Spetzler VN, Kaths JM, Barbas AS, Louis KS, *et al*. Anti-inflammatory signaling during *ex vivo* liver perfusion improves the preservation of pig liver grafts before transplantation. Liver Transplant 2016; 22: 1573–83.
136 Goldaracena N, Spetzler VN, Echeverri J, Kaths JM, Cherepanov V, Persson R, *et al*. Inducing hepatitis C virus resistance after pig liver transplantation-a proof of concept of liver graft modification using warm *ex vivo* perfusion. Am J Transplant 2017; 17: 970–8.
137 Ott HC, Matthiesen TS, Goh S-K, Black LD, Kren SM, Netoff TI, *et al*. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14: 213–21.
138 Ott HC, Clippinger B, Conrad C, Schuetz C, Pomerantseva I, Ikonomou L, *et al*. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 2010; 16: 927–33.
139 Song JJ, Kim SS, Liu Z, Madsen JC, Mathisen DJ, Vacanti JP, *et al*. Enhanced *in vivo* function of bioartificial lungs in rats. Ann Thorac Surg 2011; 92: 998–1006.
140 Gilpin SE, Guyette JP, Gonzalez G, Ren X, Asara JM, Mathisen DJ, *et al*. Perfusion decellularization of human and porcine lungs: bringing the matrix to clinical scale. J Heart Lung Transplant 2014; 33: 298–308.
141 Baptista PM, Orlando G, Mirmalek-Sani SH, Siddiqui M, Atala A, Soker S. Whole organ decellularization–a tool for bioscaffold fabrication and organ bioengineering. Conf Proc IEEE Eng Med Biol Soc 2009; 2009: 6526–9.
142 Miyoshi K, Sakagami K, Orita K. *Ex vivo* perfusion of canine pancreaticoduodenal allografts using class-II-specific monoclonal antibody delays the onset of acute rejection. Transpl Int 1992; 5 Suppl 1: S516–20.
143 Brasile L, Glowacki P, Castracane J, Stubenitsky BM. Pretransplant kidney-specific treatment to eliminate the need for systemic immunosuppression. Transplantation 2010; 90: 1294–8.
144 Martens A, Ordies S, Vanaudenaerde BM, Verleden SE, Vos R, Van Raemdonck DE, *et al*. Immunoregulatory effects of multipotent adult progenitor cells in a porcine *ex vivo* lung perfusion model. Stem Cell Res Ther 2017; 8: 159.
145 Burdorf L, Azimzadeh AM, Pierson RN. Xenogeneic lung

transplantation models. Methods Mol Biol 2012: 169–89.
146 Laird C, Burdorf L, Pierson RN. Lung xenotransplantation. Curr Opin Organ Transplant 2016; 21: 272–8.
147 Zhu B, Tong C, Guo W, Pu R, Zhang G, Wang L, *et al*. Synergistic suppression of pre-perfusion of donor livers with recipient serum and cobra venom factor treatment on hyperacute rejection following liver xenotransplantation. Acta Cir Bras 2012; 27: 301–5.
148 Cantu E, Gaca JG, Palestrant D, Baig K, Lukes DJ, Gibson SE, *et al*. Depletion of pulmonary intravascular macrophages prevents hyperacute pulmonary xenograft dysfunction. Transplantation 2006; 81: 1157–64.
149 Azimzadeh A, Meyer C, Watier H, Beller JP, Chenard-Neu MP, Kieny R, *et al*. Removal of primate xenoreactive natural antibodies by extracorporeal perfusion of pig kidneys and livers. Transpl Immunol 1998; 6: 13–22.
150 Barakat O, Abbasi S, Rodriguez G, Rios J, Wood RP, Ozaki C, *et al*. Use of decellularized porcine liver for engineering humanized liver organ. J Surg Res 2012; 173: e11–25.
151 Navarro-Tableros V, Herrera Sanchez MB, Figliolini F, Romagnoli R, Tetta C, Camussi G. Recellularization of rat liver scaffolds by human liver stem cells. Tissue Eng Part A 2015; 21: 1929–39.